Antibody evolution immunogens
The present invention relates, in general, to HIV-1 and, in particular, to broadly neutralizing HIV-1 antibodies, and to HIV-1 immunogens and to methods of using such immunogens to induce the production of broadly neutralizing HIV-1 antibodies in a subject (e.g., a human).
1. A composition comprising a recombinant HIV-1 envelope protein comprising all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 879 or SEQ ID NO: 861 and a carrier.
2. The composition according to claim 1 wherein said composition comprises a purified gp120 HIV-1 envelope protein consisting of all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 879 or SEQ ID NO: 861.
3. The composition according to claim 1 wherein the recombinant HIV-1 envelope protein is a gp140 HIV-1 envelope protein.
4. The composition according to claim 1 wherein said composition further comprises an adjuvant.
5. The composition according to claim 1 , wherein said composition comprises the recombinant HIV-1 envelope protein comprising all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 879.
6. The composition according to claim 1 , wherein said composition comprises the recombinant HIV-1 envelope protein comprising all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 861.
7. The composition according to claim 2 , wherein said composition comprises a purified gp120 HIV-1 envelope protein consisting of all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 879.
8. The composition according to claim 2 , wherein said composition comprises a purified gp120 HIV-1 envelope protein consisting of all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 861.
9. The composition according to claim 7 wherein said composition further comprises an adjuvant.
10. The composition according to claim 8 wherein said composition further comprises an adjuvant.
11. A recombinant HIV-1 envelope protein comprising all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 879 or SEQ ID NO: 861.
12. A method of inducing an immune response comprising administering to a mammal in need thereof the composition according to claim 1 in an amount sufficient to effect said induction.
13. The method according to claim 12 wherein the HIV-1 envelope protein is a purified gp120 HIV-1 envelope protein consisting of all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 879 or SEQ ID NO: 861 and is administered as a prime in a prime/boost regimen.
14. The method according to claim 12 wherein said composition is administered by injection.
15. The method according to claim 12 wherein said composition is administered intrarectally or vaginally.
16. The method according to claim 12 wherein said mammal is a human.
17. The method of claim 12 further comprising administering a nucleic acid encoding CH505 TF HIV-1 envelope as a prime in a prime/boost regimen.
18. The method according to claim 13 further comprising administering a recombinant HIV-1 envelope protein comprising all the consecutive amino acids immediately after the signal peptide in SEQ ID NO: 884 or SEQ ID NO: 866 and a recombinant HIV-1 envelope protein comprising all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 889 or SEQ ID NO: 871.
19. A method of inducing an immune response comprising administering to a mammal in need thereof the composition according to claim 9 in an amount sufficient to effect said induction.
20. A method of inducing an immune response comprising administering to a mammal in need thereof the composition according to claim 10 in an amount sufficient to effect said induction.
21. The method of claim 19 further comprising administering a recombinant HIV-1 envelope protein comprising all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 884 or SEQ ID NO: 866 and a recombinant HIV-1 envelope protein comprising all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 889 or SEQ ID NO: 871.
22. The method of claim 20 further comprising administering a recombinant HIV-1 envelope protein comprising all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 884 or SEQ ID NO: 866 and a recombinant HIV-1 envelope protein comprising all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 889 or SEQ ID NO: 871.
23. The method of claim 19 further comprising administering a nucleic acid encoding CH505 TF HIV-1 envelope as a prime in a prime/boost regimen.
24. The method of claim 20 further comprising administering a nucleic acid encoding CH505 TF HIV-1 envelope as a prime in a prime/boost regimen.